JZP-4

JZP-4 is an investigational sustained-release formulation of **quetiapine**, an atypical antipsychotic, that was developed by **Jazz Pharmaceuticals**. It was designed using a proprietary delivery technology to provide a controlled release of quetiapine, aiming to improve the tolerability and dosing profile for psychiatric conditions. The primary indication pursued for JZP-4 was **generalized anxiety disorder (GAD)**. Quetiapine's pharmacology is complex, involving antagonism at dopamine D2 and serotonin 5-HT2A receptors, as well as partial agonism at the 5-HT1A receptor. Its active metabolite, norquetiapine, also contributes to its clinical effects through potent inhibition of the norepinephrine transporter. Jazz Pharmaceuticals advanced JZP-4 into Phase 3 clinical trials for GAD; however, the development program was terminated in 2010 after the trials failed to demonstrate a statistically significant improvement over placebo on the primary efficacy endpoints.

Other names

quetiapine SRquetiapine sustained-releasequetiapine fumarate sustained-release